Clinical Trial Update: A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing cataract risk associated with quetiapine (Seroquel) and risperidone (Risperdal) in people with schizophrenia or schizoaffective d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperdal (risperidone)
• SEROQUEL (QUETIAPINE)

Snippet

Sponsor: AstraZeneca | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED | Results posted: 2011-07-13